Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy

Wojtowicz,Karolina; Januchowski,Radosław; Sosińska,Patrycja; Nowicki,Michał; Zabel,Maciej

doi:10.3892/or.2016.4656

Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy

Authors:
- Karolina Wojtowicz
- Radosław Januchowski
- Patrycja Sosińska
- Michał Nowicki
- Maciej Zabel
View Affiliations

Affiliations: Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznań, Poland, Department of Pathophysiology, Poznan University of Medical Sciences, 60-806 Poznań, Poland
Published online on: March 7, 2016 https://doi.org/10.3892/or.2016.4656
Pages: 2896-2906

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we analyzed the influence of brefeldin A (BFA) and castanospermine (CAS) on the activity, stability and localization of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) in various resistant cell lines. The impact of BFA and CAS on cell viability was assessed using the MTT test. Western blotting (WB) was performed to assess the effect of the inhibitors on the expression of the investigated proteins. Immunofluorescence was employed to assess the effect of BFA and CAS on the cellular localization of the proteins. Flow cytometry was used to verify the functional role of inhibitors on drug uptake and efflux. The MTT test showed that BFA had a significant effect on cell viability in LoVo/Dx and W1PR cell lines. WB analysis demonstrated that BFA partially blocked Pgp N-glycosylation and induced BCRP degradation and CASP 3-dependent apoptosis in W1TR cells; however, the BFA activity was p53-independent. CAS had no effect on the stability of Pgp but increased the level of non-glycosylated BCRP. The expression of p53 protein decreased in all of the cells that were treated with CAS. Immunofluorescence revealed that BFA caused a more granular Pgp signal in W1PR and BCRP in A2780T1 cells. Furthermore, BFA caused morphological changes in LoVo/Dx and W1TR cell lines. CAS also induced a granular signal in all of the cell lines, except W1TR. The flow cytometry showed higher dye accumulation in sensitive cell lines. We observed an increase in the mean fluorescence intensity (MFI) of Rho123 in LoVo/Dx cells treated with BFA and CAS, but no differences were observed in W1PR. BFA had no effect on the MFI of W1TR, but CAS led to an increase in the level of intracellular H33342 in W1TR and A2780T1 cells. These results suggest that these compounds are likely to be useful as supplements in anticancer therapy.

View Figures

View References

1	Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL and Packer NH: Cell surface protein glycosylation in cancer. Proteomics. 14:525–546. 2014. View Article : Google Scholar
2	Persidis A: Cancer multidrug resistance. Nat Biotechnol. 18(Suppl): IT18–IT20. 2000.
3	Sharom FJ: ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics. 9:105–127. 2008. View Article : Google Scholar
4	Ma H, Miao X, Ma Q, Zheng W, Zhou H and Jia L: Functional roles of glycogene and n-glycan in multidrug resistance of human breast cancer cells. IUBMB Life. 65:409–422. 2013. View Article : Google Scholar : PubMed/NCBI
5	Li K, Sun Z, Zheng J, Lu Y, Bian Y, Ye M, Wang X, Nie Y, Zou H and Fan D: In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. J Proteomics. 82:130–140. 2013. View Article : Google Scholar : PubMed/NCBI
6	Meschini S, Calcabrini A, Monti E, Del Bufalo D, Stringaro A, Dolfini E and Arancia G: Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer. 87:615–628. 2000. View Article : Google Scholar : PubMed/NCBI
7	Pastan I and Gottesman M: Multiple-drug resistance in human cancer. N Engl J Med. 316:1388–1393. 1987. View Article : Google Scholar : PubMed/NCBI
8	Wojtowicz K, Szaflarski W, Januchowski R, Zawierucha P, Nowicki M and Zabel M: Inhibitors of N-glycosylation as a potential tool for analysis of the mechanism of action and cellular localisation of glycoprotein P. Acta Biochim Pol. 59:445–450. 2012.PubMed/NCBI
9	Shapiro AB, Fox K, Lee P, Yang YD and Ling V: Functional intracellular P-glycoprotein. Int J Cancer. 76:857–864. 1998. View Article : Google Scholar : PubMed/NCBI
10	Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R and Maraldi NM: Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol. 68:226–239. 1995.PubMed/NCBI
11	Calcabrini A, Meschini S, Stringaro A, Cianfriglia M, Arancia G and Molinari A: Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells. Histochem J. 32:599–606. 2000. View Article : Google Scholar
12	Noguchi K, Katayama K and Sugimoto Y: Human ABC transporter ABCG2/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics. Pharm Genomics Pers Med. 7:53–64. 2014.
13	Nakanishi T and Ross DD: Breast cancer resistance protein (BCRP/ABCG2): Its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 31:73–99. 2012. View Article : Google Scholar
14	Wakabayashi-Nakao K, Tamura A, Furukawa T, Nakagawa H and Ishikawa T: Quality control of human ABCG2 protein in the endoplasmic reticulum: Ubiquitination and proteasomal degradation. Adv Drug Deliv Rev. 61:66–72. 2009. View Article : Google Scholar
15	Nakagawa H, Wakabayashi-Nakao K, Tamura A, Toyoda Y, Koshiba S and Ishikawa T: Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2. FEBS J. 276:7237–7252. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ferris SP, Kodali VK and Kaufman RJ: Glycoprotein folding and quality-control mechanisms in protein-folding diseases. Dis Model Mech. 7:331–341. 2014. View Article : Google Scholar : PubMed/NCBI
17	Nakajima M, Koga T, Sakai H, Yamanaka H, Fujiwara R and Yokoi T: N-Glycosylation plays a role in protein folding of human UGT1A9. Biochem Pharmacol. 79:1165–1172. 2010. View Article : Google Scholar
18	Tannous A, Pisoni GB, Hebert DN and Molinari M: N-linked sugar-regulated protein folding and quality control in the ER. Semin Cell Dev Biol. 41:79–89. 2015. View Article : Google Scholar :
19	Ruggiano A, Foresti O and Carvalho P: Quality control: ER-associated degradation: protein quality control and beyond. J Cell Biol. 204:869–879. 2014. View Article : Google Scholar : PubMed/NCBI
20	Klausner RD, Donaldson JG and Lippincott-Schwartz J: Brefeldin A: Insights into the control of membrane traffic and organelle structure. J Cell Biol. 116:1071–1080. 1992. View Article : Google Scholar : PubMed/NCBI
21	Oda K, Fujiwara T and Ikehara Y: Brefeldin A arrests the intracellular transport of viral envelope proteins in primary cultured rat hepatocytes and HepG2 cells. Biochem J. 265:161–167. 1990. View Article : Google Scholar : PubMed/NCBI
22	Misumi Y, Misumi Y, Miki K, Takatsuki A, Tamura G and Ikehara Y: Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem. 261:11398–11403. 1986.PubMed/NCBI
23	Yardin C, Terro F, Esclaire F, Rigaud M and Hugon J: Brefeldin A-induced apoptosis is expressed in rat neurons with dephosphorylated tau protein. Neurosci Lett. 250:1–4. 1998. View Article : Google Scholar : PubMed/NCBI
24	Pommepuy I, Terro F, Petit B, Trimoreau F, Bellet V, Robert S, Hugon J, Labrousse F and Yardin C: Brefeldin A induces apoptosis and cell cycle blockade in glioblastoma cell lines. Oncology. 64:459–467. 2003. View Article : Google Scholar : PubMed/NCBI
25	Shao RG, Shimizu T and Pommier Y: Brefeldin A is a potent inducer of apoptosis in human cancer cells independently of p53. Exp Cell Res. 227:190–196. 1996. View Article : Google Scholar : PubMed/NCBI
26	Lee SA, Kim YJ and Lee CS: Brefeldin A induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits focal adhesion kinase-mediated cell invasion. Basic Clin Pharmacol Toxicol. 113:329–338. 2013.PubMed/NCBI
27	Salles FT, Hespanhol AM, Jaeger RG and Marques MM: Brefeldin-A induces apoptosis in human adenoid cystic carcinoma cultured cells. Oral Oncol. 40:585–590. 2004. View Article : Google Scholar : PubMed/NCBI
28	Wlodkowic D, Skommer J and Pelkonen J: Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells. Leuk Res. 31:1687–1700. 2007. View Article : Google Scholar : PubMed/NCBI
29	Wallen E, Sellers RG and Peehl DM: Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. J Urol. 164:836–841. 2000. View Article : Google Scholar : PubMed/NCBI
30	Verovski VN, Van den Berge DL, Delvaeye MM, Scheper RJ, De Neve WJ and Storme GA: Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer. 73:596–602. 1996. View Article : Google Scholar : PubMed/NCBI
31	Hohenschutz LD, Bell EA, Jewess PJ, Leworthy DP, Pryce RJ, Arnold E and Clardy J: Castanospermine, a 1,6,7,8-tetrahydroxyoctahydroindolizine alkaloid from seeds of Castanospermum austarale. Phytochemistry. 20:811–814. 1981. View Article : Google Scholar
32	Pili R, Chang J, Partis RA, Mueller RA, Chrest FJ and Passaniti A: The α-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 55:2920–2926. 1995.PubMed/NCBI
33	Grochowicz PM, Hibberd AD, Bowen KM, Clark DA, Pang G, Grochowicz LK, Willenborg DO and Cowden WB: Synergism of castanospermine and FK 506. Transplant Proc. 27:355–356. 1995.PubMed/NCBI
34	Vlietinck AJ, De Bruyne T, Apers S and Pieters LA: Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med. 64:97–109. 1998. View Article : Google Scholar : PubMed/NCBI
35	Chang J, Block TM and Guo JT: Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions. Antiviral Res. 99:251–260. 2013. View Article : Google Scholar : PubMed/NCBI
36	Kato A, Hirokami Y, Kinami K, Tsuji Y, Miyawaki S, Adachi I, Hollinshead J, Nash RJ, Kiappes JL, Zitzmann N, et al: Isolation and SAR studies of bicyclic iminosugars from Castanospermum australe as glycosidase inhibitors. Phytochemistry. 111:124–131. 2015. View Article : Google Scholar : PubMed/NCBI
37	Schraen-Maschke S and Zanetta JP: Role of oligomannosidic N-glycans in the proliferation, adhesion and signalling of C6 glioblastoma cells. Biochimie. 85:219–229. 2003. View Article : Google Scholar : PubMed/NCBI
38	Wojtowicz K, Januchowski R, Nowicki M and Zabel M: Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines. Biomed Pharmacother. 74:49–56. 2015. View Article : Google Scholar : PubMed/NCBI
39	Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M and Zabel M: MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. BioMed Res Int. 2013:2417632013. View Article : Google Scholar : PubMed/NCBI
40	Szaflarski W, Sujka-Kordowska P, Januchowski R, Wojtowicz K, Andrzejewska M, Nowicki M and Zabel M: Nuclear localization of P-glycoprotein is responsible for protection of the nucleus from doxorubicin in the resistant LoVo cell line. Biomed Pharmacother. 67:497–502. 2013. View Article : Google Scholar : PubMed/NCBI
41	Fu D, Bebawy M, Kable EP and Roufogalis BD: Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. Int J Cancer. 109:174–181. 2004. View Article : Google Scholar : PubMed/NCBI
42	Janneh O, Owen A, Bray PG, Back DJ and Pirmohamed M: The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. Br J Pharmacol. 159:484–493. 2010. View Article : Google Scholar :
43	Rhodes T, Barrand MA and Twentyman PR: Modification by brefeldin A, bafilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (nBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R. Br J Cancer. 70:60–66. 1994. View Article : Google Scholar : PubMed/NCBI
44	Wood DJT, Rumsby MG and Warr JR: Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells. Cancer Lett. 108:41–47. 1996. View Article : Google Scholar : PubMed/NCBI
45	Marquardt D and Center MS: Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: Evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res. 52:3157–3163. 1992.PubMed/NCBI
46	Gong Y, Wang Y, Chen F, Han J, Miao J, Shao N, Fang Z and Ou Yang R: Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leuk Res. 24:769–774. 2000. View Article : Google Scholar : PubMed/NCBI
47	Togawa A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Shimamura F, Yoshidome H, Katoh A and Miyazaki M: Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-A on the resistant cell line. Pancreas. 27:220–224. 2003. View Article : Google Scholar : PubMed/NCBI
48	Labroille G, Belloc F, Bilhou-Nabera C, Bonnefille S, Bascans E, Boisseau MR, Bernard P and Lacombe F: Cytometric study of intracellular P-gp expression and reversal of drug resistance. Cytometry. 32:86–94. 1998. View Article : Google Scholar : PubMed/NCBI
49	Allan G, Ouadid-Ahidouch H, Sanchez-Fernandez EM, Risquez-Cuadro RÃ, Fernandez JÃMG, Ortiz-Mellet C and Ahidouch A: New castanospermine glycoside analogues inhibit breast cancer cell proliferation and induce apoptosis without affecting normal cells. PLoS One. 8:e764112013. View Article : Google Scholar : PubMed/NCBI
50	Durland-Busbice S and Reisman D: Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene. Leukemia. 16:2165–2167. 2002. View Article : Google Scholar : PubMed/NCBI
51	Muller PAJ, Vousden KH and Norman JC: p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 192:209–218. 2011. View Article : Google Scholar : PubMed/NCBI
52	Lin ZP, Boller YC, Amer SM, Russell RL, Pacelli KA, Patierno SR and Kennedy KA: Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: Involvement of NF-kappaB activation in drug resistance. Cancer Res. 58:3059–3065. 1998.PubMed/NCBI